RARA(17q21)基因斷裂探針

 廣州健侖生物科技?有限公司 

本司長期供應尼古丁（可替寧）檢測試劑盒，其主要品牌包括美國NovaBios、廣州健侖、廣州創侖等進口產品，國產產品，試劑盒的實驗方法是膠體金方法。

我司還有很多熒光原位雜交系列檢測試劑盒以及各種FISH基因探針和染色體探針等，。

RARA(17q21)基因斷裂探針

   本試劑盒主要用于RARA(17q21)基因斷裂的檢測，里面包括即用型雜交液和DAPI復染劑。
本試劑盒僅供科研使用。

歡迎咨詢

歡迎咨詢

以下是我司出售的部分FISH產品：

RARA(17q21)基因斷裂探針

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 

【】
【騰訊 】
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-3室

【企業文化宣傳】RARA(17q21)基因斷裂探針

每逢佳節倍思親，大家都說在“我的蛙”身上看到了自己，也看到了遠在故鄉牽掛著自己的家人。
 

 
春節臨近，很多研究者們依然扎根在實驗室忙著做實驗，還沒回到故鄉與家人團聚。一年又一年的堅持，也許枯燥，也許辛苦，研究者們卻不改初心，因為科研的目的，正是為了更好的服務于人們的健康。
 
博奧晶典科研服務提前給大家拜個早年，也請大家多多關注自己和家人的健康~
 

 
今天給大家介紹一項前列腺癌的科研成果，研究者通過系統研究，發現DNA甲基化具有作為前列腺癌非侵入式診斷標志物的潛力！
 
本研究鑒定了與前列腺癌有關的DNA甲基化位點，發現了6個候選的甲基化位點（ID：cg03052502，cg04462340，cg05163709，cg05544622，cg14466580，cg27539893），這些位點有以下特點：
1.在前列腺癌中高度特異
2.在前列腺患者尿液中檢測了其中兩個位點（cg05163709，cg27539893）
3.AUC-ROC分析顯示cg05163709（0.915）高于經典的PSA（0.769）
4.在正常組織中保守，在腫瘤組織中變化顯著
5.與年齡和地理分布無關

 
研究者找到一個甲基化位點，cg05163709與前列腺癌密切相關，支持DNA甲基化具有成為高靈敏度和特異性的診斷標志物的潛力。本研究中也對尿液中的DNA甲基化位點進行了檢測，提示可以進行非侵入性的甲基化檢測。
 

 
研究背景
 
用于診斷的前列腺特異抗原（PSA）檢測總是產生假陽性結果，并導致不必要和/或重復活組織檢查。因此迫切需要開發更靈敏更特異的診斷標志物。本研究分析了66對癌組織和相鄰正常組織中的表觀基因型甲基化位點，結果發現，與正常組織相比，前列腺癌組織的Y染色體上有6個異常的甲基化位點。
 
進一步使用PCa患者的尿液進行焦磷酸測序，發現一個甲基化位點（cg05163709）是潛在的生物標志物。通過ROC分析評估了這些異常甲基化位點的預測能力，發現cg05163709（0.915）的AUC高于PSA的AUC（0.769）。這些結果表明Y染色體上的cg05163709異常DNA甲基化具有成為高靈敏度和特異性的診斷標志物的潛力。
 

Whenever we think about the family, everyone says they see themselves on my frog and see their family in their hometown.

When the Spring Festival is approaching, many researchers are still working in the laboratory to do experiments and have not returned to their hometown to reunite with their families. Year after year's insistence may be boring, maybe hard, but researchers do not change their minds, because the purpose of scientific research is to better serve people's health.

Boao crystal code research service in advance for everyone a happy, also please pay more attention to the health of themselves and their families.

Today we introduce a scientific research achievement of prostate cancer. Through systematic research, researchers found that DNA methylation has potential as a noninvasive diagnostic marker for prostate cancer.

This study identified DNA methylation sites related to prostate cancer, and found 6 candidate methylation sites (ID:cg03052502, cg04462340, cg05163709, cg05544622, cg14466580, cg27539893). These loci have the following characteristics.
1. highly specific in prostate cancer
2. the two loci (cg05163709, cg27539893) were detected in the urine of the prostate patients.
The 3.AUC-ROC analysis showed that cg05163709 (0.915) was higher than the classic PSA (0.769).
4. conservative in normal tissues and significant changes in tumor tissue
5. has nothing to do with age and geographical distribution

The researchers found a methylation site. Cg05163709 is closely related to prostate cancer. DNA methylation is a potential marker for high sensitivity and specificity. In this study, the DNA methylation sites in urine were also detected, suggesting that noninvasive methylation can be detected.

Research background

The detection of prostate specific antigen (PSA) used for diagnosis always produces false positive results and leads to unnecessary and / or repeated biopsy. Therefore, it is urgent to develop more sensitive and specific diagnostic markers. In this study, 66 pairs of epigenetic methylation sites in cancer tissues and adjacent normal tissues were analyzed. It was found that there were 6 abnormal methylation sites on Y chromosome of prostate cancer tissues compared with normal tissues.

The urine of PCa patients was further sequenced by pyrophosphate, and a methylated site (cg05163709) was found to be a potential biomarker. The predictive ability of these abnormal methylation sites was evaluated by ROC analysis, and it was found that the AUC of cg05163709 (0.915) was higher than AUC (0.769) of PSA. These results suggest that the cg05163709 abnormal DNA methylation on the Y chromosome has the potential to be a highly sensitive and specific diagnostic marker.